» Articles » PMID: 38085800

Transgenic Amyloid Precursor Protein Mouse Models of Amyloidosis. Incomplete Models for Alzheimer's Disease but Effective Predictors of Anti-amyloid Therapies

Overview
Specialties Neurology
Psychiatry
Date 2023 Dec 12
PMID 38085800
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Amyloid precursor protein (APP) transgenic mice are models of Alzheimer's disease (AD) amyloidosis, not all of AD. Diffuse, compacted, and vascular deposits in APP mice mimic those found in AD cases.

Methods: Most interventional studies in APP mice start treatment early in the process of amyloid deposition, consistent with a prevention treatment regimen. Most clinical trials treat patients with established amyloid deposits in a therapeutic treatment regimen.

Results: The first treatment to reduce amyloid and cognitive impairment in mice was immunotherapy. The APP mouse models not only predicted efficacy, but presaged the vascular leakage called ARIA. The recent immunotherapy clinical trials that removed amyloid and slowed cognitive decline confirms the utility of these early APP models when used in therapeutic designs.

Discussion: New mouse models of AD pathologies will add to the research armamentarium, but the early models have accurately predicted responses to amyloid therapies in humans.

Citing Articles

Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti-amyloid therapies.

Morgan D, Lamb B Alzheimers Dement. 2023; 20(2):1459-1464.

PMID: 38085800 PMC: 10916971. DOI: 10.1002/alz.13566.

References
1.
Chang W, Huang X, Downs D, Cirrito J, Koelsch G, Holtzman D . Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 2010; 25(2):775-84. PMC: 3023390. DOI: 10.1096/fj.10-167213. View

2.
Chishti M, Yang D, Janus C, Phinney A, Horne P, Pearson J . Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001; 276(24):21562-70. DOI: 10.1074/jbc.M100710200. View

3.
Calderon-Garciduenas A, Duyckaerts C . Alzheimer disease. Handb Clin Neurol. 2017; 145:325-337. DOI: 10.1016/B978-0-12-802395-2.00023-7. View

4.
Lemere C, Maron R, Spooner E, Grenfell T, Mori C, Desai R . Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci. 2001; 920:328-31. DOI: 10.1111/j.1749-6632.2000.tb06943.x. View

5.
Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S . A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2001; 408(6815):979-82. DOI: 10.1038/35050110. View